AA
GILD icon

Armis Advisers’s Gilead Sciences GILD Stock Holding History

Armis Advisers’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$388K Buy
2,991
+470
+19% +$61.9K 0.04% 316
2026
Q1 		$335K Buy
2,521
+504
+25% +$70.6K 0.03% 331
2025
Q4 		$277K Buy
+2,017
New +$245K 0.03% 336

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Armis Advisers's GILD Position: Q2 2026 in Review

Armis Advisers increased its Gilead Sciences (GILD) stake by 19% in Q2 2026, buying an estimated $61.9K and bringing the position to 2,991 shares worth $388K. The position accounts for 0.04% of the portfolio, ranked #316.

Armis Advisers first reported a position in GILD in Q4 2025 and has held it in 3 quarters since. 2,271 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Armis Advisers held 2,991 shares of Gilead Sciences worth $388K as of Q2 2026.
  • Armis Advisers bought 470 Gilead Sciences shares in Q2 2026, an estimated $61.9K.
  • Gilead Sciences made up 0.04% of Armis Advisers's portfolio in Q2 2026, its #316 holding.
  • Armis Advisers first reported a position in Gilead Sciences in Q4 2025 and has held it in 3 quarters since.
  • 2,271 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Armis Advisers's 13F filing for Q2 2026, filed 7 Jul 2026.